The efficacy and role of Acemini: How to accurately target cancer cells?

Asciminib is a new type of oral targeted drug, which belongs to the tyrosine kinase inhibitor ( TKI) class of drugs and is mainly used to treat chronic myelogenous leukemia (CML). It precisely inhibits the effect of BCR-ABL1 fusion protein, blocking the growth and spread of cancer cells, thereby exerting a therapeutic effect. Unlike traditional TKI drugs such as Imatinib, aximinib has a more specific mechanism of action and can directly target specific mutations in cancer cells and precisely interfere with the growth signals of cancer cells.

Chronic myelogenous leukemia is a type of leukemia caused byBCR-ABL1 fusion gene. This gene mutation exists in the patient's cancer cells. Aceminib targets the function of the ABL1 tyrosine kinase, specifically targeting the T315I mutation type, which is common in patients with drug-resistant chronic myelogenous leukemia.

Traditional TKI drugs such as imatinib or dasatinib are often less effective against T315I mutant CML, and the introduction of aximinib provides new treatment hope for this type of patients. Aximini has shown high efficacy in clinical applications, especially in patients with drug-resistant or relapsed CML. It can effectively reduce the proliferation of leukemia cells and improve the clinical symptoms of patients. Studies have shown that aximini can reduce the activity of BCR-ABL1 fusion protein and accurately "cut off" the growth signaling pathways of cancer cells, thereby effectively preventing the progression of tumors.

In addition, the efficacy of Asiminib in patients with drug-resistant leukemia has also been verified, especially in the context of drug-resistant mutations, such asT315I mutation. Traditional drug treatments often fail, and the use of Asiminib can effectively restore the effect of treatment. The drug's targeted therapeutic mechanism can avoid systemic side effects caused by traditional chemotherapy, thereby improving patients' quality of life.

In general, aceminib has become one of the important drugs in the treatment of chronic myelogenous leukemia due to its precise targeting effect and anti-drug resistance advantages. Its use can effectively improve the cure rate and survival time of CML patients.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib